Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0050929 |
| Name | mucosal melanoma |
| Definition | A melanoma that has_material_basis_in melanocytes located_in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer cell type cancer melanoma mucosal melanoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| KIT C443S | Imatinib | mucosal melanoma | sensitive | detail... |
| BRAF V600L | Dabrafenib + Trametinib | mucosal melanoma | predicted - sensitive | detail... |
| KIT N822K | Avapritinib | mucosal melanoma | predicted - sensitive | detail... |
| KIT exon17 | Avapritinib | mucosal melanoma | predicted - sensitive | detail... |
| EML4 - ALK | Crizotinib | mucosal melanoma | sensitive | detail... |
| EML4 - ALK | Ceritinib | mucosal melanoma | sensitive | detail... |
| EML4 - ALK | Entrectinib | mucosal melanoma | sensitive | detail... |
| EML4 - ALK | ASP3026 | mucosal melanoma | sensitive | detail... |
| EML4 - ALK | Alectinib | mucosal melanoma | sensitive | detail... |
| NRAS Q61H | Trametinib | mucosal melanoma | sensitive | detail... |
| NRAS Q61L | Belvarafenib | mucosal melanoma | predicted - sensitive | detail... |
| BRAF D594G | Belvarafenib | mucosal melanoma | predicted - sensitive | detail... |
| KIT V560D | Imatinib | mucosal melanoma | predicted - sensitive | detail... |
| KIT D820Y | Imatinib | mucosal melanoma | predicted - sensitive | detail... |
| KIT K642E | Imatinib | mucosal melanoma | predicted - sensitive | detail... |
| KIT mutant | Nilotinib | mucosal melanoma | predicted - sensitive | detail... |
| KIT D820V | Nilotinib | mucosal melanoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02645149 | Phase II | Trametinib Pazopanib Ceritinib Ribociclib + Trametinib | Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) | Active, not recruiting | AUS | 0 |
| NCT02748564 | Phase II | Aldesleukin + Pembrolizumab | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Terminated | USA | 0 |
| NCT02818023 | Phase I | Cobimetinib + Pembrolizumab + Vemurafenib | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | Terminated | USA | 0 |
| NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Completed | CAN | 0 |
| NCT02978443 | Phase II | Ipilimumab + Nivolumab | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | Terminated | USA | 0 |
| NCT03220009 | Phase II | Ipilimumab + Nivolumab | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | Withdrawn | USA | 0 |
| NCT03235245 | Phase II | Binimetinib + Encorafenib Ipilimumab + Nivolumab | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) | Active, not recruiting | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | 0 |
| NCT03241186 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | Active, not recruiting | USA | 0 |
| NCT03313206 | Phase II | Pembrolizumab | Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ) | Recruiting | FRA | 0 |
| NCT03340129 | Phase II | Ipilimumab + Nivolumab | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X) | Recruiting | SWE | NOR | AUS | 0 |
| NCT03817125 | Phase I | Nivolumab + SER-401 Vancomycin Nivolumab | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) | Completed | USA | 0 |
| NCT03875079 | Phase I | Pembrolizumab + RO6874281 | A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-A, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma | Completed | USA | FRA | ESP | CAN | BEL | AUS | 1 |
| NCT03991741 | Phase I | Aldesleukin | Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors | Terminated | USA | 0 |
| NCT04042506 | Phase II | Nivolumab | SBRT as a Vaccination for Metastatic Melanoma | Withdrawn | USA | 0 |
| NCT04139902 | Phase II | Cobolimab + Dostarlimab-gxly Dostarlimab-gxly | PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) | Active, not recruiting | USA | 0 |
| NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
| NCT04318717 | Phase Ib/II | Pembrolizumab | Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma | Recruiting | USA | 0 |
| NCT04493203 | Phase II | Axitinib + Nivolumab | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | Completed | USA | 0 |
| NCT04551352 | Phase I | RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | Completed | USA | ESP | DNK | CAN | BEL | AUS | 0 |
| NCT04570332 | Phase II | BO-112 + Pembrolizumab | BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203) | Completed | FRA | ESP | 0 |
| NCT04577807 | Phase II | PVSRIPO + unspecified PD-1 antibody PVSRIPO | PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma | Completed | USA | 0 |
| NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
| NCT04830124 | Phase II | ALKS 4230 | Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6) | Terminated | USA | ITA | GBR | ESP | CAN | AUS | 2 |
| NCT04987996 | Phase II | Pembrolizumab Belapectin + Pembrolizumab | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | Withdrawn | USA | 0 |
| NCT05061134 | Phase II | Ceralasertib + Durvalumab Ceralasertib | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
| NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | IRL | ESP | CAN | AUS | 2 |
| NCT05089370 | Phase Ib/II | Decitabine and Cedazuridine + Nivolumab | Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma | Active, not recruiting | USA | 0 |
| NCT05098210 | Phase I | NeoVax + Nivolumab + Poly ICLC | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer | Recruiting | USA | 0 |
| NCT05111574 | Phase II | Nivolumab Cabozantinib + Nivolumab | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | Recruiting | USA | CAN | 0 |
| NCT05384496 | Phase II | Axitinib + Ipilimumab + Nivolumab Axitinib + Nivolumab | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | Recruiting | USA | 0 |
| NCT05415072 | Phase Ib/II | DYP688 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | Active, not recruiting | USA | NLD | FRA | ESP | DEU | CHE | AUS | 0 |
| NCT05428007 | Phase II | Ipilimumab + Nivolumab and relatlimab-rmbw + Sarilumab | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | Recruiting | USA | 0 |
| NCT05482074 | Phase II | Olaparib | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | Withdrawn | 0 | |
| NCT05545969 | Phase II | Lenvatinib + Pembrolizumab | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM) | Withdrawn | AUS | 0 |
| NCT05628883 | Phase I | Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | Active, not recruiting | USA | 0 |
| NCT05913388 | Phase II | Pembrolizumab GB1211 + Pembrolizumab | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
| NCT06319196 | Phase II | Nivolumab Nivolumab and relatlimab-rmbw | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma (ClearMe) | Recruiting | CAN | 0 |
| NCT06594991 | Phase II | Cemiplimab + Fianlimab + Ipilimumab | A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma | Recruiting | USA | 0 |
| NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06651151 | Phase II | LTX-315 + Pembrolizumab | NeoLIPA: Neoadjuvant LTX-315 in Combination With Pembrolizumab in Resectable Stage III/IV Melanoma (NeoLIPA) | Recruiting | NOR | 0 |
| NCT06660420 | Phase I | PRAME-TCR-NK cells Cyclophosphamide + Fludarabine | Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) | Recruiting | USA | 0 |
| NCT06961357 | Phase Ib/II | Interleukin-12 CD40L-augmented TILs Cyclophosphamide + Fludarabine | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | Recruiting | USA | 0 |
| NCT06999980 | Phase II | Ipilimumab + Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab + Relatlimab | A Phase II, Randomised Clinical Trial of Nivolumab and Ipilimumab Combined With Relatlimab for Patients With Resectable Advanced Melanoma Identified as Poor Responders to Immunotherapy Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) (Neo IRENIE) | Not yet recruiting | AUS | 0 |
| NCT07070232 | Phase Ib/II | BNT327 + YL202 YL202 Itraconazole + YL202 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Recruiting | USA | GBR | AUS | 0 |
| NCT07155317 | Phase II | Ipilimumab + Nivolumab | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | Recruiting | USA | 0 |